Anne Elizabeth Borgman - 01 May 2025 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ David Pauling as attorney-in-fact for Anne E. Borgman
Issuer symbol
STRO
Transactions as of
01 May 2025
Net transactions value
-$26,439
Form type
4
Filing time
05 May 2025, 17:45:10 UTC
Previous filing
04 Mar 2025
Next filing
22 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Borgman Anne Elizabeth CHIEF MEDICAL OFFICER C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO /s/ David Pauling as attorney-in-fact for Anne E. Borgman 05 May 2025 0001886388

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Options Exercise $0 +53,125 +100% $0.000000 106,223 01 May 2025 Direct
transaction STRO Common Stock Options Exercise $0 +15,938 +15% $0.000000 122,161 01 May 2025 Direct
transaction STRO Common Stock Tax liability $26,439 -24,709 -20% $1.07 97,452 01 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -53,125 -71% $0.000000 21,875 01 May 2025 Common Stock 53,125 Direct F2, F3, F4
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -15,938 -47% $0.000000 17,812 01 May 2025 Common Stock 15,938 Direct F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Anne Elizabeth Borgman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3 The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date.
F4 The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025.
F5 The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.